

### Who can administer

Administration RESTRICTED - see Appendix 1

### Important information

- See 'Monitoring requirements' overleaf
- With regards to the unlicensed (systemic) use in acute pain management note that adjust dose for BMI greater than 30kg/m<sup>2</sup>. CAP dose for obese patients (see below)<sup>(ref 4)</sup>
- Unlicensed for the indications given below

### Available preparations

Lidocaine 2% ampoule 100mg per 5mL (20mg per ml)

Lidocaine 2% ampoule 400mg per 20mL (20mg per ml)

Lidocaine 1% ampoule 50mg per 5ml (10mg per ml)

Lidocaine 1% ampoule 200mg per 20ml (10mg per ml)

### Reconstitution

Already in solution

### Infusion fluids

Glucose 5% or Sodium chloride 0.9%

### Methods of intravenous administration

### Bolus intravenous injection (FOR USE IN CARDIOLOGY)

• Administer required dose at a rate of 25 to 50mg per minute (ref 1)

# Continuous intravenous infusion (FOR USE IN CARDIOLOGY) (administer using an electronically controlled infusion device)

- To prepare an 0.2% infusion<sup>(ref 1)</sup>:
- Remove 50ml from a Glucose 5% or Sodium chloride 0.9% 500ml infusion bag and discard. Add 50ml of the lidocaine 2% solution to the bag
- This solution then contains 1000mg lidocaine in 500ml 2mg/ml (0.2%)
- Adjust rate as per 'Dose'

### Bolus intravenous injection (FOR USE IN PAIN MANAGEMENT)

- Refer to the GUH Guideline for Intravenous Lidocaine Infusion for Acute pain- available on QPulse CLN-NM-0541
- The guideline recommends a 1 to 1.5mg/kg slow IV injection to be administered over three to five minutes then see continuous infusion below

# Continuous intravenous infusion (FOR USE IN PAIN MANAGEMENT) (administer using an electronically controlled infusion device)

- Refer to Guideline for Intravenous Lidocaine Infusion for Acute pain- available on QPulse CLN-NM-0541
- Prepare syringe by drawing up 50ml of 1% Lidocaine (10mg/ml) in a 50 ml syringe. **This will be a lidocaine solution of 500mg in 50ml**
- Administer via a syringe driver

# Dose in adults

# VENTRICULAR ARRYTHMIAS, especially after myocardial infarction in patients without gross circulatory collapse $^{(ref\,1)}$

• Give 100mg as a **bolus injection** over a few minutes (50mg in lighter patients, or those whose circulation is severely impaired)

### Followed immediately by an intravenous infusion:

- Give 4mg per minute for thirty minutes (= 120ml/hour of 0.2% infusion),
- then 2mg per minute for two hours (= 60ml/hour of 0.2% infusion),
- then 1mg per minute (= 30ml/hour of 0.2% infusion);
- **STOP** as soon as cardiac rhythm normalises or toxicity is noticed (and inform team)
- Reduce concentration further if infusion continued beyond twenty four hours
- Important: ECG monitoring and specialist advice required for infusion
- If an intravenous infusion is not immediately available the initial intravenous injection can be repeated if necessary once or twice at intervals of not less than 10 minutes

# PAIN CONTROL (unlicensed indication) (refer to Q pulse document CLN-NM-0541: Intravenous lidocaine infusion for acute pain management)

- May only be prescribed by Pain team or relevant anaesthetist
- Give a bolus dose of 1 to 1.5mg/kg over 3 to 5 minutes (cap dose for obese patients see table 2) as a slow intravenous injection
- Follow with a continuous infusion. Start with 1mg/kg/hour **CAP dose in obesity** (speak to your anasthesia consultant, pain team or critical care pharmacist before exceeding **100mg/hour**)
- Do not re-bolus
- Consult with the Pain team before making any increases (ref 3)
- Infusion rate can vary from 0.5mg/kg/hour to 1.5mg/kg/hour
- Duration: 48 to 72 hours usually, but longer durations have been used

#### Table 1: Lidocaine STARTING doses for PAIN MANAGEMENT INDICATION ONLY

| 500mg Lidocaine in 50ml (10mg/ml). Based on dose of $1mg/kg/hr$ with BMI < $30kg/m^2$ |                    |             |                    |  |
|---|--------------------|-------------|--------------------|--|
| Weight (kg)   | Rate of infusion   | Weight (kg) | Rate of infusion   |  |
| 50kg  | 50mg/hr (5ml/hr)   | 80kg        | 80mg/hr (8ml/hr)   |  |
| 55kg  | 55mg/hr (5.5ml/hr) | 85kg        | 85mg/hr (8.5ml/hr) |  |
| 60kg  | 60mg/hr (6ml/hr)   | 90kg        | 90mg/hr (9ml/hr)   |  |
| 65kg  | 65mg/hr (6.5ml/hr) | 95kg        | 95mg/hr (9.5ml/hr) |  |
| 70kg  | 70mg/hr (7ml/hr)   | 100kg       | 100mg/hr (10ml/hr) |  |
| 75kg  | 75mg/hr (7.5ml/hr) |             |                    |  |

Renal impairment: Use with caution in patients with severe renal impairment as it may accumulate

**Hepatic impairment:** Use with caution due to increased risk of side-effects (ref 1). The manufacturer advise dose reduction in such cases.

# Monitoring

- ECG monitoring required for infusion and resuscitation facilities should be available
- Monitor for excessive dose: (drowsiness or dizziness) (ref 4)
- Common or very common side effects (may indicate serious toxicity): bradycardia and hypotension (may lead to cardiac arrest); dizziness, drowsiness and paraesthesia (particularly if injection is too rapid); confusion, convulsions. In all such circumstances contact a senior physician. <sup>(ref 4)</sup>
- **Pain management:** refer to lidocaine pain guidelines QPulse document CLN-NM-0541: Intravenous lidocaine infusion for acute pain management

### Further information

• Following intravenous injection lidocaine has a short duration of action (lasting for 15 to 20 minutes)

#### Table 2: Dosing weight if BMI of 30kg/m<sup>2</sup> or more

| Height | Dosing weight if BMI of 30kg/m2 or more, with 100kg cap | Maximum starting infusion rate (ml/hour)<br>of a 500mg/50mL (10mg/mL) solution<br>(1mg/kg/hour dose) |
|--------|---|--|
| 140cm  | 59kg  | 5.9  |
| 145cm  | 63kg  | 6.3  |
| 150cm  | 68kg  | 6.8  |
| 155cm  | 72kg  | 7.2  |
| 160cm  | 77kg  | 7.7  |
| 165cm  | 82kg  | 8.2  |
| 170cm  | 87kg  | 8.7  |
| 175cm  | 92kg  | 9.2  |
| 180cm  | 97kg  | 9.7  |
| 185cm  | 100kg   | 10   |
| 190cm  | 100kg   | 10   |
| 195cm  | 100kg   | 10   |
| 200cm  | 100kg   | 10   |

### Storage

Store below  $25^{\circ}C$ 

### References

SPC 1% w/v Lidocaine March 2023

SPC 2% w/v Lidocaine March 2023

- 1: BNF accessed online 11/12/2024
- 2: Injectable Medicines Guide Medusa accessed online 11/12/2024
- 3: Email correspondence with Dr O Finnerty on 26/1/18
- 4: QPulse document CLN-NM-0541

### Therapeutic classification

Class 1 Antiarrhythmic agent